Stroke. Stroke, not specified as haemorrhage or infarction
Conditions
Interventions
Intervention 1: Treatment group will receive 7.5 gr (15 cc) of magnesium sulfate SID for 5 days. Intervention 2: control group will receive 15 cc of placebo SID for 5 days.
Treatment - Drugs
Placebo
Treatment group will receive 7.5 gr (15 cc) of magnesium sulfate SID for 5 days.
control group will receive 15 cc of placebo SID for 5 days.
Sponsors
Tehran University of medical sciences (Vice Chancellor of research)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: _Inclusion criteria: stroke confirmed by CT scan; Consent form was signed by family member; The patient was undergo treatment with amiodarone; The patient had Atrial fibrilation _Exclusion criteria: Serum creatinin greater than 2 mg/dl; Hypermagnasemia occur in the patient; The patient do not receive treatment for more than 24 hours.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infarct size. Timepoint: Before and after of intervention. Method of measurement: CT Scan.;Immunoglobulin G, Immunoglobulin A, S100B Protein, SNSE Protein. Timepoint: Before and after of intervention. Method of measurement: Elisa Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality, Vascular resistance, Delirium, Mechanical ventilation index, Multi-Organ Dysfunction Score, APACHE II Score, SOFA Score, Candida Score, Hospitalization Period. Timepoint: Before and after of intervention. Method of measurement: Questionnaire.;White blood cell count, platelet count, Hemoglobin, Alanine transaminase, Aspartate transaminase, Serum Creatinine, Serum Potassium, Serum Natrium, Serum Lactate, Total Serum Bilirubin, Blood PH. Timepoint: Before and after of intervention. Method of measurement: Blood and Serum Analysis.;Interleukin 6, Interleukin 8, Platelet-activating factor, Plasminogen activator inhibitor-1, CAM-1 Protein, Elastin Fiber Protein, E-Selectin Protein, NGAL Protein, EGF Protein, TGF Protein. Timepoint: Before and after of intervention. Method of measurement: Elisa Kit.;Functional Residual Capacity, Respiratory Rate, Total Lung Capacity, Vital Capacity, Residual Volume, (Maximum Ventilatory Volume, Forced Expiratory Volume. Timepoint: During the study. Method of measurement: Ventilator.;Glasgow Coma Scale, National Institutes of Health Stroke Scale. Timepoint: During the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYunes Panahi
Baqiyatallah University of medical sciences
Outcome results
None listed